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A fundamental tenet in cardiac biology, namely that the heart is a postmitotic organ incapable 
of regeneration, has recently been challenged. According to the traditional belief, the number 
of cardiac myocytes we are born with is all we will have for the rest of our lives. If myocytes 
die (e.g. as the result of infarction), they cannot be renewed. This is why myocardial 
infarction (MI) and its consequences, such as congestive heart failure, continue to be a major 
cause of death worldwide despite the considerable therapeutic advances that have been made 
over the past decades.  
 
In one attempt to evade this dilemma, cell replacement strategies are currently being 
investigated for their therapeutic potential to restore cardiac function. Indeed, a growing body 
of evidence from both basic animal studies and clinical trials indicates that cell-based 
strategies using different stem cell populations such as embryonic stem cells, skeletal 
myoblasts, haematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem 
cells might be promising.1,2 According to these studies, improvements in clinical symptoms, 
left-ventricular function, and myocardial perfusion are feasible with cell therapy. However, 
there is an ongoing controversy about the underlying mechanisms and, particularly, the 
capability of the different implanted progenitor cells to transdifferentiate and what the 
essential prerequisites for this transdifferentiation might be. Only on understanding these 
mechanisms and, likely, through the appropriate priming and engineering of the cells to be 
implanted regeneration by this approach might be achieved.  
 
Another approach to induce cardiac regeneration for repair after injury would be to reverse 
the terminal differentiation, as many mammalian tissues respond to injury by activating 
committed progenitor cells or by triggering proliferation of differentiated cells that re-enter 
cell cycle. Although several groups have described the presence of progenitor or stem cells 
that can differentiate into cardiac myocytes,3,4 there is still much debate and confusion in the 
field regarding their potential for cardiac myocyte differentiation and myocardial repair.5,6 
Limited induction of DNA synthesis in the heart has been described in response to various 
stimuli.7,8 Yet, there has been little evidence for cytoplasmic division or cytokinesis in 
mammals. In contrast to cardiomyocytes from lower vertebrates, which are well endowed to 
divide postnatally,9,10 proliferation ceases in the perinatal mammalian heart in conjunction 
with the downregulation of cyclin-dependent kinase (cdk) activities. Myocytes undergo an 
additional round of DNA synthesis and nuclear mitosis without cytokinesis (acytokinetic 
mitosis) that leaves the majority of adult cardiac myocytes binucleated in most species. 
Beyond this stage of differentiation, further increases in cardiac mass are possible only 
through an increase in cell size or hypertrophy.  
 
The report by Tamamori-Adachi et al.11 in the current issue of Cardiovascular Research 
provides encouraging evidence that manipulation of positive and negative regulators of cell 
cycle control mechanisms successfully promotes cardiomyocyte division and, hence, might 
yield new strategies for the treatment of ischaemic heart failure. The study continues previous 
work12 and shows that adenoviral delivery of S-phase kinase-associated protein 2 (Skp2), an 
ubiquitin ligase that mediates degradation of the cell cycle inhibitor p27, together with 
nuclear-targeted cyclin D1 (D1NLS) and Cdk4 results in increased proliferation (BrdU-
positive cells and expression of Ki67) and increased mitosis (phosphorylation of histone H3, 
Aurora B and Survivin) after coronary artery ligation in rats. Furthermore, gene expression 
profiling by microarray analysis of rat neonatal cardiomyocytes expressing D1NLS and Cdk4 
in culture showed gene activation for a subset of G1/S, S phase, G2/M, and M phase 
checkpoints, thereby further suggesting the feasibility of profound and effective manipulation 
of cell cycle control in heart cells. Indeed, the authors demonstrated cytokinesis in 
cardiomyocytes in vivo with daughter cells staining positive for tropomyosin. To note, 
cytokinesis is important since in normal adult hearts a number of cardiomyocytes are 
polyploid and/or multinucleated. Moreover, nuclear hyperplasia and multinucleation have 
been associated with cell hypertrophy as mechanism of growth in the postnatal heart. The 
current study complements the previous attempts to overcome the proliferation arrest in adult 
cardiomyocytes by manipulation of cell cycle control. In these earlier studies, transgenic mice 
overexpressing cyclin D2 showed higher rates of DNA synthesis and signs of mitosis (H3P) 
or newly formed myocardium after infarction,13,14 likely by phosphorylation of cyclin D2-
target retinoblastoma gene product (pRb) being prevented. Accordingly, a cyclin D2 
knockout prevented the increase in the relative heart weight after transverse aortic 
constriction.15 Furthermore, mice lacking Rb and p130 showed signs of persisting 
proliferation of cardiomyocytes during adulthood (BrdU, H3P), along with the expression of 
c-Myc, E2F, and CycE, and increased activity of Cdk2, Cdk4, and Cdk6.16 There is also 
strong evidence that inhibition of p38 MAPK in combination with FGF1 stimulation, 
promotes hypertrophy and cytokinesis in adult cardiomyocytes.17,18 Interestingly, inhibition of 
p38 MAPK augments growth factor-mediated induction of all phases of the cell cycle and 
substantially enhances the proliferative capacity of mammalian cardiomyocytes. 
Additionally, p38 activity prevented upregulation of factors required for karyokinesis and 
cytokinesis, suggesting a role for p38 in G2/M checkpoint control. Furthermore, cyclin A2 
induced cardiomyocyte mitosis (H3P), increased myocardial proliferation, and improved 
heart function after MI,19,20 while ectopic expression of cyclin B1 and Cdk2 induced mitosis-
promoting factor (MPF) activity in adult cardiomyocytes, which resulted in a mitotic 
phenotype, but no complete cell division.21 Taken together, the data in the current study 
further confirm that manipulation of cell cycle regulation might offer reasonable strategies for 
cardiac regeneration and treatment of ischaemic heart failure. The significance of the induced 
myocyte proliferation is strengthened by the observed protection against cardiac dysfunction 
and heart failure in an ischaemia/reperfusion-induced acute MI model.  
 
There are, however, still unanswered questions that need to be addressed. First, the 
quantitative contribution of the observed myocyte proliferation per se to the observed 
protective effects is not clear. Besides technical limitations (assessment and variability of the 
initial MI size), it is quite possible that cardio-protective effects (i.e. smaller MI size and 
improved function) are mediated by multiple mechanisms as stated by the authors. These may 
include paracrine effects by induction or suppression of cytokines and growth factors, 
resulting in reduced rate of apoptosis and increased vascularization as also reported in this 
study. Also, the temporal correlation of these angiogenic and anti-apoptic effects to cell 
proliferation is not completely conclusive. Moreover, the role of other factors contributing to 
post-ischaemic heart failure (i.e. hypertrophy, remodelling) has not been studied, and the 
occurrence of transient dedifferentiation of the myofibrils in the proliferating adult 
cardiomyocytes has not been investigated. It may also be speculated that the observed 
enhanced proliferation occurred in young cardiomyocytes simply because the cells derive 
from the (limited) pool of cardiac progenitor cells. If so, then additional cell cycle regulators 
need to be targeted in adult cardiomyocytes for a more substantial onset of proliferation. 
Alternatively, this goal may also be achieved by the development of more efficient methods 
for gene delivery. Finally, the adenoviral delivery for gene transfer always leaves the 
possibility of a somewhat dysregulated proliferation. As suggested by the authors, this 
potential problem has to be considered in a clinical context. Alternative methods like FGF1 
stimulation/p38 MAPK inhibition, periostin, or IGF1 are less specific but more easily 
adjustable.  
 
Although the report by Tamamori-Adachi et al.11 emphasizes the rationale for continuing 
research on promoting re-entry of myocytes into the cell cycle for cardiac regeneration, the 
fundamental shift in paradigm from the heart being strictly a postmitotic organ to one that 
carries some, although arrested, regenerative capacities clearly has a long way to go before 
such a therapeutic strategy can be applied in the clinical setting. In addition to taking into 
account safety considerations, it will be a key prerequisite to identify the appropriate master 
regulators of cell cycle control or the most advantageous combinations thereof, which was the 
aim of the current report.  
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